Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
WATERTOWN, Mass., March 06, 2017 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 29th Annual ROTH Conference on Monday, March 13, 2017 at 8:00 a.m. Pacific Time at the Ritz Carlton Hotel in Dana Point, CA.
A live audio webcast of the ROTH presentation will be available on the company’s website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Argot Partners Maeve Conneighton 206-899-4940 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected]
